WO2000033161A3 - Methods to reduce variance in treatment studies using genotyping - Google Patents

Methods to reduce variance in treatment studies using genotyping Download PDF

Info

Publication number
WO2000033161A3
WO2000033161A3 PCT/US1999/028582 US9928582W WO0033161A3 WO 2000033161 A3 WO2000033161 A3 WO 2000033161A3 US 9928582 W US9928582 W US 9928582W WO 0033161 A3 WO0033161 A3 WO 0033161A3
Authority
WO
WIPO (PCT)
Prior art keywords
treated
control
methods
treatment
efficacy
Prior art date
Application number
PCT/US1999/028582
Other languages
French (fr)
Other versions
WO2000033161A9 (en
WO2000033161A2 (en
Inventor
Hugh Y Rienhoff Jr
Hywel B Jones
Original Assignee
Kiva Genetics Inc
Hugh Y Rienhoff Jr
Hywel B Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiva Genetics Inc, Hugh Y Rienhoff Jr, Hywel B Jones filed Critical Kiva Genetics Inc
Priority to MXPA01005513A priority Critical patent/MXPA01005513A/en
Priority to CA002350069A priority patent/CA2350069A1/en
Priority to AU31082/00A priority patent/AU3108200A/en
Priority to JP2000585735A priority patent/JP2003501005A/en
Priority to EP99965095A priority patent/EP1155361A2/en
Publication of WO2000033161A2 publication Critical patent/WO2000033161A2/en
Publication of WO2000033161A3 publication Critical patent/WO2000033161A3/en
Publication of WO2000033161A9 publication Critical patent/WO2000033161A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The present invention provides methods, computer programs and computerized systems useful for evaluating the efficacy of various types of treatment procedures (e.g., clinical trials) as a function of the genotype of a subject. By matching treatment and control groups genetically (100) the methods and systems of the invention reduce the total variance of the study, thereby allowing trials examining the efficacy or effect of treatment procedures to be conducted with fewer subjects, with increased confidence values, and/or with increased precision or discriminatory power. Certain methods of the invention involve selecting treated and control subpopulations of subjects from treated and control populations for similarity in polymorphic profile (102), wherein the treated and control populations have been treated with a treatment and control procedure, respectively. A determination is then made whether there is a statistically significant difference (104) in a test parameter between the treated and control subpopulations as an assessment of the test procedure (108).
PCT/US1999/028582 1998-12-02 1999-12-01 Methods to reduce variance in treatment studies using genotyping WO2000033161A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA01005513A MXPA01005513A (en) 1998-12-02 1999-12-01 Methods to reduce variance in treatment studies using genotyping.
CA002350069A CA2350069A1 (en) 1998-12-02 1999-12-01 Methods to reduce variance in treatment studies using genotyping
AU31082/00A AU3108200A (en) 1998-12-02 1999-12-01 Methods to reduce variance in treatment studies using genotyping
JP2000585735A JP2003501005A (en) 1998-12-02 1999-12-01 Methods for reducing variance in genotype-based treatment studies
EP99965095A EP1155361A2 (en) 1998-12-02 1999-12-01 Methods to reduce variance in treatment studies using genotyping

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11066898P 1998-12-02 1998-12-02
US60/110,668 1998-12-02

Publications (3)

Publication Number Publication Date
WO2000033161A2 WO2000033161A2 (en) 2000-06-08
WO2000033161A3 true WO2000033161A3 (en) 2000-11-02
WO2000033161A9 WO2000033161A9 (en) 2001-04-19

Family

ID=22334245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028582 WO2000033161A2 (en) 1998-12-02 1999-12-01 Methods to reduce variance in treatment studies using genotyping

Country Status (6)

Country Link
EP (1) EP1155361A2 (en)
JP (1) JP2003501005A (en)
AU (1) AU3108200A (en)
CA (1) CA2350069A1 (en)
MX (1) MXPA01005513A (en)
WO (1) WO2000033161A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
CN103710429B (en) 2005-11-29 2016-03-30 剑桥企业有限公司 Markers for breast cancer
BRPI1011979A2 (en) 2009-06-01 2020-10-06 Genetic Technologies Limited methods for risk assessment of breast cancer.
JP5656159B2 (en) * 2009-08-24 2015-01-21 独立行政法人理化学研究所 Markers for predicting the effects of interferon therapy
JP6114584B2 (en) * 2013-03-14 2017-04-12 株式会社スタージェン Method for determining standard values for measurement data, method for evaluating measurement data using standard values
AU2015327756B2 (en) 2014-09-30 2018-01-04 Genetic Technologies Limited Methods for assessing risk of developing breast cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5075217A (en) * 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5075217A (en) * 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOULD K. L.: "Invasive Procedures In Acute Myocardial Infarction: are they benenficial", THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 272, no. 11, September 1994 (1994-09-01), pages 891 - 893, XP000933575 *
HAMMOND ET. AL.: "Double-bind study of selective decontamination of the digestive tract in intensive care", LANCET, vol. 340, no. 8810, July 1992 (1992-07-01), pages 5 - 9, XP000929528 *
SHULTZ K. F.: "Assessing the Quality of Randomization from Reports of Controlled Trials Publised in Obstetrics and Gyneclology Journals", THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 272, no. 2, July 1994 (1994-07-01), pages 125 - 128, XP000933968 *

Also Published As

Publication number Publication date
MXPA01005513A (en) 2003-07-14
WO2000033161A9 (en) 2001-04-19
WO2000033161A2 (en) 2000-06-08
EP1155361A2 (en) 2001-11-21
JP2003501005A (en) 2003-01-14
AU3108200A (en) 2000-06-19
CA2350069A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
AU2003263834A1 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease
UA86582C2 (en) Method for treatment of huntington's chorea with eicosapentaenoic acid
HK1057217A1 (en) Method of diagnosing alzheimer' s disease on the basis of a gene transcript pattern
WO2004041348A3 (en) Apparatus and method for pattern delivery of radiation and biological characteristic analysis
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2000052204A3 (en) Gene expression in bladder tumors
BR0301719A (en) Process for diagnosing myocardial infarction and / or risk stratification of acute coronary syndrome, set of reagents to make this diagnosis and use it
AU2319495A (en) Method and means for detecting and treating disorders in the blood coagulation cascade
DE69423346T2 (en) QUICK PROCEDURE FOR DNA SEQUENCING AND DIAGNOSTIC APPLICATIONS
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
DE69715669T2 (en) DETECTION OF A GENETIC PREPOSITION FOR DIABETIC RETINOPATHY WITH THE RISK OF THE LOSS OF VISION
EA199700355A1 (en) METHOD OF DIAGNOSTIC SCHIZOPHRENIA
WO2000033161A3 (en) Methods to reduce variance in treatment studies using genotyping
WO2004044164A3 (en) Method for identifying risk of melanoma and treatments thereof
CA2248672A1 (en) Measuring and processing data in reaction to stimuli
WO2000070340A3 (en) Materials and methods relating to disease diagnosis
AU2304697A (en) Diagnostic method and apparatus
WO2003062794A3 (en) Method of using electromagnetic absorption or perturbation spectra to diagnose and detect abnormalities in cells, tissues and organisms
AU2003250938A1 (en) Method for determination of thymidine kinase 1 activity and the use thereof
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
RS20060255A (en) Quick test for the diagnosis of alzheimer's disease
ATE329638T1 (en) DEVICE FOR ESTABLISHING AN ARTIFICIAL ISOLATED CIRCUIT IN A TARGET AREA OF A HUMAN OR ANIMAL BODY
WO2007103303A3 (en) Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2350069

Country of ref document: CA

Ref country code: CA

Ref document number: 2350069

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 585735

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005513

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999965095

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999965095

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999965095

Country of ref document: EP